Logo image of ERNA

ERNEXA THERAPEUTICS INC (ERNA) Stock Fundamental Analysis

NASDAQ:ERNA - Nasdaq - US1140822099 - Common Stock - Currency: USD

1.92  -0.04 (-2.04%)

After market: 1.8805 -0.04 (-2.06%)

Fundamental Rating

1

Overall ERNA gets a fundamental rating of 1 out of 10. We evaluated ERNA against 558 industry peers in the Biotechnology industry. ERNA has a bad profitability rating. Also its financial health evaluation is rather negative. ERNA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ERNA has reported negative net income.
ERNA had a negative operating cash flow in the past year.
ERNA had negative earnings in each of the past 5 years.
ERNA had a negative operating cash flow in each of the past 5 years.
ERNA Yearly Net Income VS EBIT VS OCF VS FCFERNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

ERNA has a Return On Assets of -911.44%. This is amonst the worse of the industry: ERNA underperforms 97.49% of its industry peers.
Industry RankSector Rank
ROA -911.44%
ROE N/A
ROIC N/A
ROA(3y)-333.38%
ROA(5y)-301.4%
ROE(3y)-1264.52%
ROE(5y)-959.07%
ROIC(3y)N/A
ROIC(5y)N/A
ERNA Yearly ROA, ROE, ROICERNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

1.3 Margins

ERNA has a Gross Margin of 93.46%. This is amongst the best in the industry. ERNA outperforms 94.62% of its industry peers.
ERNA's Gross Margin has improved in the last couple of years.
ERNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y6.07%
ERNA Yearly Profit, Operating, Gross MarginsERNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

0

2. Health

2.1 Basic Checks

ERNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ERNA has been increased compared to 1 year ago.
Compared to 5 years ago, ERNA has more shares outstanding
ERNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ERNA Yearly Shares OutstandingERNA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
ERNA Yearly Total Debt VS Total AssetsERNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

ERNA has an Altman-Z score of -76.66. This is a bad value and indicates that ERNA is not financially healthy and even has some risk of bankruptcy.
ERNA has a Altman-Z score of -76.66. This is amonst the worse of the industry: ERNA underperforms 94.98% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -76.66
ROIC/WACCN/A
WACC8.67%
ERNA Yearly LT Debt VS Equity VS FCFERNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

ERNA has a Current Ratio of 0.21. This is a bad value and indicates that ERNA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ERNA (0.21) is worse than 95.16% of its industry peers.
A Quick Ratio of 0.21 indicates that ERNA may have some problems paying its short term obligations.
With a Quick ratio value of 0.21, ERNA is not doing good in the industry: 94.98% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.21
ERNA Yearly Current Assets VS Current LiabilitesERNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ERNA have decreased strongly by -46.89% in the last year.
Looking at the last year, ERNA shows a very strong growth in Revenue. The Revenue has grown by 369.30%.
Measured over the past years, ERNA shows a very negative growth in Revenue. The Revenue has been decreasing by -50.61% on average per year.
EPS 1Y (TTM)-46.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.51%
Revenue 1Y (TTM)369.3%
Revenue growth 3YN/A
Revenue growth 5Y-50.61%
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ERNA Yearly Revenue VS EstimatesERNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2023 2024 5M 10M 15M 20M 25M
ERNA Yearly EPS VS EstimatesERNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2021 0 -500 -1K -1.5K -2K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ERNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERNA Price Earnings VS Forward Price EarningsERNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ERNA Per share dataERNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ERNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ERNEXA THERAPEUTICS INC

NASDAQ:ERNA (7/15/2025, 8:00:01 PM)

After market: 1.8805 -0.04 (-2.06%)

1.92

-0.04 (-2.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12
Earnings (Next)08-11 2025-08-11
Inst Owners2.39%
Inst Owner Change0%
Ins Owners9.45%
Ins Owner Change59.64%
Market Cap14.13M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 26.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-93.66
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.96
FCFYN/A
OCF(TTM)-1.92
OCFYN/A
SpS0.07
BVpS-0.81
TBVpS-1.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -911.44%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.46%
FCFM N/A
ROA(3y)-333.38%
ROA(5y)-301.4%
ROE(3y)-1264.52%
ROE(5y)-959.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y6.07%
F-Score4
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.21
Altman-Z -76.66
F-Score4
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)70.57%
Cap/Depr(5y)70.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.51%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)369.3%
Revenue growth 3YN/A
Revenue growth 5Y-50.61%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.47%
OCF growth 3YN/A
OCF growth 5YN/A